CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 86 enrolled
Drug / intervention
Fluzone® (IM) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02141581
NCT02141581Phase 4Completed
CompareCT.gov

Vaccination and Infection: Indicators of Immunological Health and Responsiveness. Project 1: Plasmablast Trafficking and Antibody Response in Influenza Vaccination;

Stanford University·interventional·Posted May 19, 2014·Updated May 7, 2018

In Brief

A Phase 4 clinical trial evaluating Fluzone® (IM), Fluzone® Intradermal (ID), and 1 other intervention for Influenza. Completed, enrolled 86 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the responses to licensed trivalent, inactivated influenza vaccine (TIV) delivered by different routes: intramuscular (IM) and intradermal (ID) and to the live, attenuated influenza vaccine (LAIV) administered intranasally -- all given to generally healthy male and female adult volunteers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 4CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedMay 19, 2014
Enrollment StartAug 1, 2011
Primary CompletionDec 1, 2014
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 12.1 years ago

Interventions

Fluzone® (IM)biological

This vaccine is given intramuscularly (IM)

Fluzone® Intradermal (ID)biological

This vaccine is given intradermally (ID)

2011-2012 FluMist®biological

This vaccine is given intranasally